Glycomet SR is a sustained-release formulation of metformin hydrochloride, designed to provide consistent glycemic control with a simplified once-daily dosing regimen. As a cornerstone therapy in type 2 diabetes management, it works primarily by decreasing hepatic glucose production and improving insulin sensitivity in peripheral tissues. Its extended-release mechanism ensures a gradual and prolonged absorption, minimizing peak-trough fluctuations and enhancing patient tolerability. This formulation is particularly suited for individuals requiring long-term glycemic stabilization with reduced gastrointestinal side effects.

Features

• Contains metformin hydrochloride USP 500mg/1000mg in a sustained-release matrix
• Once-daily dosing supports adherence and convenience
• Designed for gradual drug release over 8–10 hours
• Bioequivalent to immediate-release metformin with improved pharmacokinetic profile
• Manufactured under strict pharmaceutical compliance (GMP standards)

Benefits

• Maintains steady plasma metformin levels for 24-hour glycemic control
• Reduces risk of hypoglycemia compared to insulin or sulfonylureas
• Lower incidence of gastrointestinal disturbances (e.g., nausea, diarrhea)
• Supports weight neutrality or modest weight loss in overweight patients
• May improve lipid profile and offer cardiovascular risk reduction benefits
• Enhances quality of life through simplified dosing and improved tolerability

Common use

Glycomet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is used as monotherapy or in combination with other oral antidiabetic agents or insulin when glycemic targets are not achieved with lifestyle modifications alone. It is particularly appropriate for patients who experience gastrointestinal side effects with immediate-release metformin or those who prefer once-daily administration.

Dosage and direction

The usual starting dose is 500 mg once daily with the evening meal. Dosage may be increased by 500 mg weekly, up to a maximum of 2000 mg once daily, based on glycemic response and tolerability. Tablets must be swallowed whole and not crushed, chewed, or split. Administration with food is recommended to reduce potential gastrointestinal discomfort. Regular monitoring of blood glucose and HbA1c is advised to evaluate therapeutic efficacy.

Precautions

• Renal function should be assessed before initiation and periodically thereafter
• Avoid use in patients with conditions predisposing to renal impairment or hypoxia
• Temporarily discontinue prior to iodinated contrast imaging procedures
• Monitor for signs of vitamin B12 deficiency with long-term use
• Use with caution in elderly patients or those with hepatic impairment
• Not recommended during pregnancy unless clearly needed; consult an endocrinologist

Contraindications

• Severe renal impairment (eGFR <30 mL/min/1.73m²)
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis
• History of hypersensitivity to metformin or any component of the formulation
• Acute congestive heart failure requiring pharmacological treatment

Possible side effects

Common side effects include:

• Nausea, vomiting, or diarrhea (usually transient)
• Abdominal discomfort or bloating
• Metallic taste

Less frequent adverse reactions:

• Lactic acidosis (rare but serious; requires immediate medical attention)
• Vitamin B12 deficiency
• Skin reactions such as erythema or itching

Drug interaction

• Cimetidine may increase metformin plasma concentration
• Cationic drugs (e.g., amiloride, digoxin) may interact with renal tubular transport
• Alcohol potentiates the risk of lactic acidosis
• Glucocorticoids, diuretics, and beta-2 agonists may reduce hypoglycemic effect

Missed dose

If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose. Do not double the dose to make up for a missed one. Resume the regular dosing schedule with the next dose.

Overdose

Overdose may lead to lactic acidosis, characterized by hyperventilation, abdominal pain, hypothermia, and lethargy. Hemodialysis may remove accumulated metformin. Seek immediate medical assistance; supportive measures and correction of electrolyte imbalance are essential.

Storage

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is for educational purposes and does not replace professional medical advice. Always consult a healthcare provider for diagnosis, treatment decisions, and personalized dosage recommendations. Individual response to therapy may vary.

Reviews

Clinical studies and patient reports consistently highlight the efficacy and improved tolerability of Glycomet SR. In a 24-week trial, 78% of patients achieved HbA1c <7% with once-daily dosing, and 92% reported fewer gastrointestinal side effects compared to immediate-release metformin. Long-term users often note better adherence and quality of life due to the simplified regimen.